Literature DB >> 26241675

Artificial microRNAs against the viral E6 protein provoke apoptosis in HPV positive cancer cells.

Anaëlle Charlotte Bonetta1, Laurent Mailly2, Eric Robinet2, Gilles Travé1, Murielle Masson1, François Deryckere3.   

Abstract

High-risk human papillomavirus (HPV) types 16 and 18 are associated with more than 70% of cervical cancer cases. The oncoprotein E6 is multifunctional and has numerous cellular partners. The best-known activity of E6 is the polyubiquination of the pro-apoptotic tumor suppressor p53, targeting it for degradation by the 26S proteasome. Loss of p53 triggers genomic instability and favors cancer development. Here, we generated recombinant adenovirus (Ad) vectors expressing artificial microRNAs directed against HPV16 E6 (Ad16_1) or HPV18 E6 (Ad18_2). E6-knockdown was observed in HeLa after treatment with Ad18_2 and in SiHa with Ad16_1. Western-blot experiments found an increase in p53 levels after treatment in both cell lines. Cell death was observed in both cell lines after knockdown of E6. Further analysis such as cleavage of caspases (3 and 7) as well as of PARP1 indicated that treated HeLa and SiHa cells underwent apoptosis. The growth of HeLa-derived tumors developed in nude mice was significantly reduced after intra-tumoral injection of Ad18_2. Therefore, vectorisation of artificial miRNA against E6 oncoprotein by means of recombinant adenoviruses might represent a valuable therapeutic approach for treating HPV-positive cancers.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenovirus; Cancer therapy; Cervical cancer; Gene therapy; RNA interference

Mesh:

Substances:

Year:  2015        PMID: 26241675     DOI: 10.1016/j.bbrc.2015.07.144

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  The Dysregulation of MicroRNAs in the Development of Cervical Pre-Cancer-An Update.

Authors:  Pui-Wah Choi; Tin Lun Liu; Chun Wai Wong; Sze Kei Liu; Yick-Liang Lum; Wai-Kit Ming
Journal:  Int J Mol Sci       Date:  2022-06-27       Impact factor: 6.208

Review 2.  Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer.

Authors:  Momeneh Ghanaat; Nasser Hashemi Goradel; Arash Arashkia; Nasim Ebrahimi; Sajjad Ghorghanlu; Ziba Veisi Malekshahi; Esmail Fattahi; Babak Negahdari; Hami Kaboosi
Journal:  Acta Pharmacol Sin       Date:  2021-02-25       Impact factor: 6.150

Review 3.  Targeted Gene Delivery Therapies for Cervical Cancer.

Authors:  Ángela Áyen; Yaiza Jiménez Martínez; Houria Boulaiz
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

Review 4.  Delivery of cancer therapies by synthetic and bio-inspired nanovectors.

Authors:  Tina Briolay; Tacien Petithomme; Morgane Fouet; Nelly Nguyen-Pham; Christophe Blanquart; Nicolas Boisgerault
Journal:  Mol Cancer       Date:  2021-03-24       Impact factor: 27.401

Review 5.  Structural Insights in Multifunctional Papillomavirus Oncoproteins.

Authors:  Irina Suarez; Gilles Trave
Journal:  Viruses       Date:  2018-01-15       Impact factor: 5.048

6.  Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling.

Authors:  Surendra Sharma; Karl Munger
Journal:  mBio       Date:  2020-06-16       Impact factor: 7.867

Review 7.  High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis.

Authors:  Nicole S L Yeo-Teh; Yoshiaki Ito; Sudhakar Jha
Journal:  Int J Mol Sci       Date:  2018-06-08       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.